Targeting Inflammation Driven by HMGB1

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Apr 9

PMID 32265930

Citations 265

Authors

Huan Yang

Haichao Wang

Ulf Andersson

Affiliations

Soon will be listed here.

Abstract

High mobility group box 1 (HMGB1) is a highly conserved, nuclear protein present in all cell types. It is a multi-facet protein exerting functions both inside and outside of cells. Extracellular HMGB1 has been extensively studied for its prototypical alarmin functions activating innate immunity, after being actively released from cells or passively released upon cell death. TLR4 and RAGE operate as the main HMGB1 receptors. Disulfide HMGB1 activates the TLR4 complex by binding to MD-2. The binding site is separate from that of LPS and it is now feasible to specifically interrupt HMGB1/TLR4 activation without compromising protective LPS/TLR4-dependent functions. Another important therapeutic strategy is established on the administration of HMGB1 antagonists precluding RAGE-mediated endocytosis of HMGB1 and HMGB1-bound molecules capable of activating intracellular cognate receptors. Here we summarize the role of HMGB1 in inflammation, with a focus on recent findings on its mission as a damage-associated molecular pattern molecule and as a therapeutic target in inflammatory diseases. Recently generated HMGB1-specific inhibitors for treatment of inflammatory conditions are discussed.

Citing Articles

Adolescent binge alcohol exposure accelerates Alzheimer's disease-associated basal forebrain neuropathology through proinflammatory HMGB1 signaling.

Fisher R, Matheny L, Ankeny S, Qin L, Coleman Jr L, Vetreno R Front Aging Neurosci. 2025; 17:1531628.

PMID: 40046779 PMC: 11880232. DOI: 10.3389/fnagi.2025.1531628.

Baicalein Reduces Pyroptosis of Acinar Cells in Hyperlipidemic Acute Pancreatitis by Inhibiting M1 Polarization of Macrophages via the HMGB1/TLR4/NLRP3 Pathway.

Wang X, Zhou Y, Liu Y, Mo T, Chen Z, Zhang Y Inflammation. 2025; .

PMID: 40042793 DOI: 10.1007/s10753-025-02254-z.

Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection.

Shirey K, Romerio A, Shaik M, Leake D, Palmer C, Skupinska N Innate Immun. 2025; 31:17534259241313201.

PMID: 40033742 PMC: 11877469. DOI: 10.1177/17534259241313201.

Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.

Rykova E, Klimontov V, Shmakova E, Korbut A, Merkulova T, Kzhyshkowska J Int J Mol Sci. 2025; 26(4).

PMID: 40004134 PMC: 11854991. DOI: 10.3390/ijms26041670.

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.

Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).

PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.

References

Xiang H, Hu B, Li Z, Li J . Dexmedetomidine controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Inflammation. 2014; 37(5):1763-70. DOI: 10.1007/s10753-014-9906-1. View

Tsoyi K, Jang H, Nizamutdinova I, Kim Y, Lee Y, Kim H . Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol. 2010; 162(7):1498-508. PMC: 3057288. DOI: 10.1111/j.1476-5381.2010.01126.x. View

Yang H, Wang H, Levine Y, Gunasekaran M, Wang Y, Addorisio M . Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight. 2016; 1(7). PMC: 4902170. DOI: 10.1172/jci.insight.85375. View

Kokkola R, Li J, Sundberg E, Aveberger A, Palmblad K, Yang H . Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003; 48(7):2052-8. DOI: 10.1002/art.11161. View

Feldman P, Due M, Ripsch M, Khanna R, White F . The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain. J Neuroinflammation. 2012; 9:180. PMC: 3488576. DOI: 10.1186/1742-2094-9-180. View

Chavan S, Huerta P, Robbiati S, Valdes-Ferrer S, Ochani M, Dancho M . HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med. 2012; 18:930-7. PMC: 3459473. DOI: 10.2119/molmed.2012.00195. View

Ju Z, Chavan S, Antoine D, Dancho M, Tsaava T, Li J . Sequestering HMGB1 via DNA-conjugated beads ameliorates murine colitis. PLoS One. 2014; 9(8):e103992. PMC: 4134190. DOI: 10.1371/journal.pone.0103992. View

Fu L, Liu K, Wake H, Teshigawara K, Yoshino T, Takahashi H . Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpine-induced status epilepticus in mice. Sci Rep. 2017; 7(1):1179. PMC: 5430706. DOI: 10.1038/s41598-017-01325-y. View

Rosas-Ballina M, Ochani M, Parrish W, Ochani K, Harris Y, Huston J . Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A. 2008; 105(31):11008-13. PMC: 2504833. DOI: 10.1073/pnas.0803237105. View

10.

Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H . Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol. 2008; 28(10):1825-30. DOI: 10.1161/ATVBAHA.107.150631. View

11.

Nishida T, Tsubota M, Kawaishi Y, Yamanishi H, Kamitani N, Sekiguchi F . Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology. 2016; 365:48-58. DOI: 10.1016/j.tox.2016.07.016. View

12.

Andersson U, Tracey K . HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139-62. PMC: 4536551. DOI: 10.1146/annurev-immunol-030409-101323. View

13.

Aneja R, Tsung A, Sjodin H, Gefter J, Delude R, Billiar T . Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J Leukoc Biol. 2008; 84(5):1326-34. PMC: 2567896. DOI: 10.1189/jlb.0108030. View

14.

Han Y, Yuan F, Deng C, He F, Zhang Y, Shen H . Metformin decreases LPS-induced inflammatory response in rabbit annulus fibrosus stem/progenitor cells by blocking HMGB1 release. Aging (Albany NY). 2019; 11(22):10252-10265. PMC: 6914423. DOI: 10.18632/aging.102453. View

15.

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

16.

Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z . Macrophage endocytosis of high-mobility group box 1 triggers pyroptosis. Cell Death Differ. 2014; 21(8):1229-39. PMC: 4085529. DOI: 10.1038/cdd.2014.40. View

17.

Nakamura Y, Morioka N, Abe H, Zhang F, Hisaoka-Nakashima K, Liu K . Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1. PLoS One. 2013; 8(8):e73640. PMC: 3749159. DOI: 10.1371/journal.pone.0073640. View

18.

Yang Y, Li S, Yang Q, Shi Y, Zheng M, Liu Y . Resveratrol reduces the proinflammatory effects and lipopolysaccharide- induced expression of HMGB1 and TLR4 in RAW264.7 cells. Cell Physiol Biochem. 2014; 33(5):1283-92. DOI: 10.1159/000358696. View

19.

Goldenberg N, Hu Y, Hu X, Volchuk A, Zhao Y, Kucherenko M . Therapeutic Targeting of High-Mobility Group Box-1 in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019; 199(12):1566-1569. PMC: 7125426. DOI: 10.1164/rccm.201808-1597LE. View

20.

Wang H, Bloom O, Zhang M, Vishnubhakat J, Ombrellino M, Che J . HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285(5425):248-51. DOI: 10.1126/science.285.5425.248. View